GENE ONLINE|News &
Opinion
Blog

2021-04-29| ChinaTechnology

AstraZeneca, Geneseeq Sign Collaborative Deal to Build Bio Center in China

by Tyler Chen
Share To

China has been a huge market for global biotech and pharmaceutical firms to invest in. To establish an additional headquarter in China, Geneseeq Technology, a precision oncology company, has collaborated with AstraZeneca to build a Bio-Diagnostic Innovation Center in Guangzhou, China. This is Geneseeq’s fourth core laboratory in the country.

Focus on Early Detection of Cancer

Early detection has a big impact on the survival rate of cancer patients, and it’s one of Geneseeq’s key market focuses. Dr. Yang Shao, The founder and CEO of Geneseeq China, pointed out that “the spotlight for the future of cancer care is on the full-course management approach to bring greater benefits to patients, including perioperative monitoring for early-to-mid stage cancers, and cancer early screening and detection.”

The innovation center will leverage Geneseeq’s cancer diagnostics tools and AstraZeneca’s experience in oncology therapeutics to provide an improved stand-of-care solution and scalable diagnostic tools to Chinese patients. It is expected to create a program that can bring disease diagnosis, treatment, and rehabilitation together.

The Bio-Diagnostic Innovation Center in Guangzhou will be Geneseeq’s fourth laboratory in South China other than Nanjing, Shanghai, and Beijing.

Long Term Investment in China

Founded in Toronto in 2008, Geneseeq established a headquarter in Nanjing in 2013 to develop genomic diagnostic tools on lung cancer, gastrointestinal cancer, breast cancer, prostate cancer for the China market. In December 2019, Geneseeq secured a $114 million investment in a Series D financing round led by China Reform Holdings and other investors such as Lilly Asia Ventures, SoftBank China Venture Capital, and SoftBank Group.

In March 2021, Geneseeq teamed up with Illumina to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer patients in China. The collaboration aims to combine Illumina’s sequencing platform with Geneseeq’s genomic profiling panel to detect genomic alterations in 425 cancer-related genes.

Related Article: China’s Pharma Industry is Booming with Talents and Startups. What Makes All the Rage?

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Amgen Out-Licenses Two Therapies to Fosun Pharma to Expand Presence in China
2022-06-28
AstraZeneca, Ionis’ ATTR Drug Edges Closer to US Approval With Latest Trial Win
2022-06-22
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top